COMT inhibition with tolcapone does not affect carbidopa pharmacokinetics in parkinsonian patients on levodopa/carbidopa (Sinemet®)

British Journal of Clinical Pharmacology

Volumn 48, Issue 3, 1999, Pages 449-452

  Jorga, Karin M ^a   Nicholl, David J ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

COMT inhibition; Levodopa carbidopa; Parkinson's disease; Pharmacokinetics; Tolcapone

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; TOLCAPONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG ELIMINATION; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; DRUG COMBINATIONS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0032867858     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00027.x     Document Type: Article

References (12)

1. Reilly DK, Rivera-Calimlim L, van Dyke D. Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther 1980; 28: 278-286.
2. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913-919.
3. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 1990; 66: 317-323.
4. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994; 25: 813-824.
5. Jorga KM, Sedek G. Effect of the novel COMT-inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations. Neurology 1995; 45: A291.
6. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-dopa pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995; 18: 333-337.
7. Kurth MC, Adler CH, Saint Hilaire M, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997; 48: 81-87.
8. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997; 49: 665-671.
9. Vickers S, Stuart E, Bianchine J, et al. Metabolism of carbidopa [(-)-L-alpha-hydrazino-3, 4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate], an aromatic amino acid decarboxylase inhibitor, in the rat, dog, rhesus monkey, and man. Drug Metab Dispos 1974; 2: 9-22.
10. Vickers S, Stuart E, Hucker H. Further studies on the metabolism of carbidopa, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate, in the human, rhesus monkey, dog, and rat. J Med Chem 1975; 18: 134-138.
11. Gibaldi M, Perrier D. Pharmacokinetics 2nd edn. New York: Marcel Dekker 1982.
12. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995; 18: 46-57.